2022. The first data on international multicenter clinical study RheoSTAT-CP0691 on the efficacy and safety of Rheosorbilact® infusion in therapy of purulent peritonitis. Perioperaciina Medicina. 5, 1 (May 2022), 34–46. DOI:https://doi.org/10.31636/prmd.v5i1.5.